These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29792714)

  • 1. Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.
    Jaiteh M; Zeifman A; Saarinen M; Svenningsson P; Bréa J; Loza MI; Carlsson J
    J Med Chem; 2018 Jun; 61(12):5269-5278. PubMed ID: 29792714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.
    Cruz-Monteagudo M; Borges F; Cordeiro MNDS; Helguera AM; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Perera-Sardina Y; Perez-Castillo Y
    Curr Neuropharmacol; 2017 Nov; 15(8):1117-1135. PubMed ID: 28093976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands.
    Perez-Castillo Y; Helguera AM; Cordeiro MNDS; Tejera E; Paz-Y-Mino C; Sanchez-Rodriguez A; Borges F; Cruz-Monteagudo M
    Curr Neuropharmacol; 2017 Nov; 15(8):1107-1116. PubMed ID: 28067172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
    Załuski M; Schabikowski J; Schlenk M; Olejarz-Maciej A; Kubas B; Karcz T; Kuder K; Latacz G; Zygmunt M; Synak D; Hinz S; Müller CE; Kieć-Kononowicz K
    Bioorg Med Chem; 2019 Apr; 27(7):1195-1210. PubMed ID: 30808606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.
    Rodríguez D; Gao ZG; Moss SM; Jacobson KA; Carlsson J
    J Chem Inf Model; 2015 Mar; 55(3):550-63. PubMed ID: 25625646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.
    Stössel A; Schlenk M; Hinz S; Küppers P; Heer J; Gütschow M; Müller CE
    J Med Chem; 2013 Jun; 56(11):4580-96. PubMed ID: 23631427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
    Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
    Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-Based Virtual Screening Using Tailored Ensembles: A Prioritization Tool for Dual A2AAdenosine Receptor Antagonists / Monoamine Oxidase B Inhibitors.
    Helguera AM; Perez-Castillo Y; D S Cordeiro MN; Tejera E; Paz-Y-Miño C; Sánchez-Rodríguez A; Teijeira M; Ancede-Gallardo E; Cagide F; Borges F; Cruz-Monteagudo M
    Curr Pharm Des; 2016; 22(21):3082-96. PubMed ID: 26932160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A
    Falsini M; Squarcialupi L; Catarzi D; Varano F; Betti M; Dal Ben D; Marucci G; Buccioni M; Volpini R; De Vita T; Cavalli A; Colotta V
    J Med Chem; 2017 Jul; 60(13):5772-5790. PubMed ID: 28590753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A
    Rohilla S; Bansal R; Kachler S; Klotz KN
    Bioorg Chem; 2019 Jun; 87():601-612. PubMed ID: 30933785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Novel and Selective Adenosine A
    Tian S; Wang X; Li L; Zhang X; Li Y; Zhu F; Hou T; Zhen X
    J Chem Inf Model; 2017 Jun; 57(6):1474-1487. PubMed ID: 28463561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary studies of berberine and its semi-synthetic derivatives as a promising class of multi-target anti-parkinson agents.
    Ribaudo G; Zanforlin E; Canton M; Bova S; Zagotto G
    Nat Prod Res; 2018 Jun; 32(12):1395-1401. PubMed ID: 28691859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents.
    Agrawal N; Mishra P
    Comput Biol Chem; 2019 Apr; 79():63-72. PubMed ID: 30731360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Phyto-chemicals from Ocimum basilicum for the Treatment of Parkinson's Disease using In Silico Approach.
    Mubashir N; Fatima R; Naeem S
    Curr Comput Aided Drug Des; 2020; 16(4):420-434. PubMed ID: 32883197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High ligand efficiency quinazoline compounds as novel A
    Bolteau R; Duroux R; Laversin A; Vreulz B; Shiriaeva A; Stauch B; Han GW; Cherezov V; Renault N; Barczyk A; Ravez S; Coevoet M; Melnyk P; Liberelle M; Yous S
    Eur J Med Chem; 2022 Nov; 241():114620. PubMed ID: 35933788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of the adenosine A
    Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A
    Masih A; Singh S; Agnihotri AK; Giri S; Shrivastava JK; Pandey N; Bhat HR; Singh UP
    Neurosci Lett; 2020 Sep; 735():135222. PubMed ID: 32619652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.